Identification of biomarkers for predicting new-onset atrial fibrillation: a systematic review and meta-analysis
Clinical Scorecard: Biomarker Discovery for Anticipating New-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis
At a Glance
Category Detail
Condition New-onset atrial fibrillation (AF) Key Mechanisms Atrial remodelling and dysfunction; biomarkers reflecting myocardial stress, inflammation, endothelial dysfunction, and pro-thrombotic states Target Population General adult population without prior or postoperative AF Care Setting Clinical and preventive cardiology settings for early diagnosis and risk stratification
Key Highlights
Eighteen biomarkers, notably NT-proBNP and sVCAM-1, are associated with increased risk of new-onset AF. Nine biomarkers, including ADAMTS13, are linked to a lower incidence of AF. Meta-analysis confirms elevated NT-proBNP significantly increases AF risk (HR 1.37), and lipoprotein(a) modestly increases AF incidence. Guideline-Based Recommendations
Diagnosis
Early diagnosis of AF remains challenging due to asymptomatic or silent presentations. Biomarkers such as NT-proBNP and sVCAM-1 show potential to improve early detection and risk stratification. Current guidelines acknowledge uncertain roles of biomarkers in decision-making but recognize their prognostic value. Management
Recognition and staging of atrial cardiopathy can facilitate early treatment and preventive measures. Biomarker levels may guide preventive management strategies though require further validation. Preventive management should focus on stroke and major adverse cardiovascular event reduction. Monitoring & Follow-up
Regular assessment of biomarker levels could aid in monitoring risk progression in high-risk patients. Large-scale prospective studies are needed to optimize biomarker utility in clinical monitoring. Risks
Delayed diagnosis of AF increases risk of stroke, heart failure, dementia, and mortality. Underdiagnosis due to silent AF leads to higher medical costs and adverse outcomes. Patient & Prescribing Data
Patients without prior or postoperative AF at risk for new-onset AF
Biomarker-guided risk stratification may inform early intervention strategies; however, clinical application awaits further validation.
Clinical Best Practices
Incorporate biomarker assessment (e.g., NT-proBNP, sVCAM-1) alongside clinical evaluation for early AF risk detection. Use a stepwise approach to characterize atrial cardiopathy to guide preventive care. Consider biomarker profiles reflecting myocardial stress, inflammation, and endothelial dysfunction in risk stratification. Promote large-scale prospective studies to validate biomarker utility before routine clinical implementation. References
